{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:16:42Z","timestamp":1783487802648,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202306100051"],"award-info":[{"award-number":["202306100051"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejca.2026.116829","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T15:44:22Z","timestamp":1779551062000},"page":"116829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab"],"prefix":"10.1016","volume":"243","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7967-1023","authenticated-orcid":false,"given":"Laura H.","family":"Bukkems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan G.C.","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2241-252X","authenticated-orcid":false,"given":"Marie-Rose","family":"Crombag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-7902","authenticated-orcid":false,"given":"Daphne","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J.M.A.","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn","family":"Theelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van der Hulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6426","authenticated-orcid":false,"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6080-6183","authenticated-orcid":false,"given":"Juli\u00ebtte","family":"Zwaveling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0665-2160","authenticated-orcid":false,"given":"Jeroen","family":"Hiltermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-8131","authenticated-orcid":false,"given":"Robin M.J.M.","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter H.","family":"van Geffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-2153","authenticated-orcid":false,"given":"Michel","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs H.","family":"Oude Munnink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-6995","authenticated-orcid":false,"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Jan A.R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116829_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14737140.2016.1123626","article-title":"Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer","volume":"16","author":"Dang","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2026.116829_bib2","unstructured":"Highlights of Prescribing Information for Keytruda 2017, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125514s013lbl.pdf ; accessed 2 February 2026."},{"key":"10.1016\/j.ejca.2026.116829_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for Pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116829_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for Pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116829_bib5","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.21037\/tlcr-24-111","article-title":"Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancer","volume":"13","author":"Moeller","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2026.116829_bib6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.21037\/tlcr-24-63","article-title":"Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration?","volume":"13","author":"Inoue","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2026.116829_bib7","unstructured":"Administration USFaD. FDA approves Pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection. 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection; accessed 2 February 2026."},{"key":"10.1016\/j.ejca.2026.116829_bib8","unstructured":"Ministry of Health, Kingdom of the Netherlands. Report on specialized medical care 2022. https:\/\/www.rijksoverheid.nl\/documenten\/rapporten\/2022\/06\/08\/monitor-medisch-specialistische-zorg-2022 ; accessed 2 October 2023."},{"key":"10.1016\/j.ejca.2026.116829_bib9","unstructured":"Buntz B. 50 best-selling pharmaceuticals of 2022: market leaders and trends. Drug Discov Dev 2023. https:\/\/www.drugdiscoverytrends.com\/50-of-2022s-best-selling-pharmaceuticals\/ ; accessed 3 February 2026."},{"key":"10.1016\/j.ejca.2026.116829_bib10","doi-asserted-by":"crossref","unstructured":"MERCK. Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results. 2025. https:\/\/www.merck.com\/news\/merck-announces-fourth-quarter-and-full-year-2024-financial-results\/ ; accessed 2 February 2026.","DOI":"10.1016\/j.fopow.2025.03.013"},{"key":"10.1016\/j.ejca.2026.116829_bib11","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1007\/s12325-025-03365-7","article-title":"A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer","volume":"42","author":"De Cock","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejca.2026.116829_bib12","unstructured":"U.S. Food and Drug Administration Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1). 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetic-based-criteria-supporting-alternative-dosing-regimens-programmed-cell-death-receptor ; accessed 2 February 2026."},{"key":"10.1016\/j.ejca.2026.116829_bib13","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41416-024-02659-x","article-title":"Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients","volume":"130","author":"Puszkiel","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116829_bib14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cpt.875","article-title":"Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis","volume":"103","author":"Ogungbenro","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2026.116829_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107950","article-title":"Real-world overall survival after alternative dosing for Pembrolizumab in the treatment of non-small cell lung cancer: a nationwide retrospective cohort study with a non-inferiority primary objective","volume":"196","author":"Grit","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116829_bib16","doi-asserted-by":"crossref","unstructured":"Song G., Erman M., Martinengo G.L., Kocsis J., Kunta G., Wang M., et al. Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous Pembrolizumab across indications. Eur J Cancer 2025; Nov 17:230:115711.","DOI":"10.1016\/j.ejca.2025.115711"},{"key":"10.1016\/j.ejca.2026.116829_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","article-title":"Subcutaneous versus intravenous Pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116829_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/psp4.12139","article-title":"Model-based characterization of the pharmacokinetics of Pembrolizumab: a humanized Anti-PD-1 monoclonal antibody in advanced solid tumors","volume":"6","author":"Ahamadi","year":"2017","journal-title":"CPT Pharmacomet Syst Pharm"},{"key":"10.1016\/j.ejca.2026.116829_bib19","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1016\/j.annonc.2024.08.1315","article-title":"1258MO Low dose versus standard dose Pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: results of the pre-planned interim analysis of the NVALT-30 clinical trial","volume":"35","author":"van den Heuvel","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116829_bib20","unstructured":"ClinicalTrials.gov. Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC, Dedication 2023. NCT04909684, https:\/\/clinicaltrials.gov\/study\/NCT04909684 ; accessed 2 February 2026."},{"key":"10.1016\/j.ejca.2026.116829_bib21","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/annonc\/mdw174","article-title":"Systematic evaluation of Pembrolizumab dosing in patients with advanced non-small-cell lung cancer","volume":"27","author":"Chatterjee","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116829_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.tox.2013.07.009","article-title":"PopGen: a virtual human population generator","volume":"315","author":"McNally","year":"2014","journal-title":"Toxicology"},{"key":"10.1016\/j.ejca.2026.116829_bib23","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and Pembrolizumab","volume":"23","author":"Malmberg","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116829_bib24","unstructured":"Medicijnkosten.nl. KEYTRUDA INFVLST CONC 25MG\/ML FLACON 4 ML. 2025. https:\/\/www.medicijnkosten.nl\/medicijn?artikel=KEYTRUDA+INFVLST+CONC+25MG%2FML+FLACON+4ML&id=85bf8970309cc9bde819cec562ee13dc ; accessed 2 February 2026."},{"key":"10.1016\/j.ejca.2026.116829_bib25","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jval.2024.06.003","article-title":"Market entry agreements for innovative pharmaceuticals subject to indication broadening: a case study for Pembrolizumab in The Netherlands","volume":"27","author":"Heine","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.ejca.2026.116829_bib26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/10781552241255287","article-title":"A cost comparison of Pembrolizumab: fixed and weight-based dosing","volume":"31","author":"Slee","year":"2025","journal-title":"J Oncol Pharm Pr"},{"key":"10.1016\/j.ejca.2026.116829_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e14616","article-title":"Toxicity of weight-based vs. flat dosing for immune checkpoint inhibitors in patients with low weight: retrospective analysis from a tertiary care center","volume":"42","author":"Hamad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116829_bib28","article-title":"5PSQ-034\u2005Fixed vs weight-based dosing of Pembrolizumab for patients under 80 kg, based on observed ADRs in one cancer setting","volume":"30","author":"Fortuna","year":"2023","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.ejca.2026.116829_bib29","article-title":"Pharmacoeconomic evaluation of weight-based vs fixed-dose Pembrolizumab for non-small cell lung cancer in China","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.116829_bib30","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/cam4.2888","article-title":"Economics of alternative dosing strategies for Pembrolizumab and nivolumab at a single academic cancer center","volume":"9","author":"Hall","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.116829_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2020.100604","article-title":"A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human hyaluronidase PH20 administered intravenously in healthy volunteers","volume":"93","author":"Printz","year":"2020","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.ejca.2026.116829_bib32","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of Pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116829_bib33","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s11523-025-01185-x","article-title":"Weight-based Pembrolizumab dosing at 4 mg\/kg every 6 weeks leads to exposures below approved doses with unestablished efficacy: a pharmacokinetic model-based simulation analysis","volume":"20","author":"Lala","year":"2025","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2026.116829_bib34","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/jcph.6108","article-title":"Pharmacokinetics of dexamethasone in children and adolescents with obesity","volume":"64","author":"Wen","year":"2024","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116829_bib35","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/pharmaceutics16121548","article-title":"Description and modeling of relevant demographic and laboratory variables in a large oncology cohort to generate virtual populations","volume":"16","author":"P\u00e9rez-Ramos","year":"2024","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.ejca.2026.116829_bib36","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s10928-024-09929-4","article-title":"Generation of realistic virtual adult populations using a model-based copula approach","volume":"51","author":"Guo","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ejca.2026.116829_bib37","unstructured":"The European Medicines Agency (EMA). Modelling and Simulation: Questions and Answers \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-and-development\/scientific-guidelines\/clinical-pharmacology-pharmacokinetics\/modelling-simulation-questions-answers#model-based-approaches-for-approval-of-alternative-dosing-regimens-and-routes-of-administration-of-anti-pd-1-and-pd-l1-monoclonal-antibodies-13030\u3009 accessed 2 February 2026."},{"key":"10.1016\/j.ejca.2026.116829_bib38","unstructured":"Nederlandse Vereniging van Ziekenhuisapothekers (NVZA). NVZA-advies hybride doseren nivolumab en Pembrolizumab 2023. \u3008https:\/\/nvza.nl\/wp-content\/uploads\/Advies-hybride-doseren-nivolumab-en-Pembrolizumab.pdf\u3009; accessed 2 February 2026."},{"key":"10.1016\/j.ejca.2026.116829_bib39","unstructured":"Zorginstituut Nederland. Notitie - Adviezen over off-labelgebruik bij doelmatigheidsinitiatieven dure geneesmiddelen. 2024. \u3008https:\/\/www.zorginstituutnederland.nl\/documenten\/2024\/10\/08\/notitie-off-labelgebruik-bij-doelmatigheidsinitiatieven-dure-geneesmiddelen\u3009 ; accessed 2 February 2026."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:47:02Z","timestamp":1783486022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"alternative-id":["S0959804926006106"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116829","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116829"}}